{"id":391468,"date":"2020-12-02T06:53:06","date_gmt":"2020-12-02T11:53:06","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=391468"},"modified":"2020-12-02T06:53:06","modified_gmt":"2020-12-02T11:53:06","slug":"adamas-announces-agreement-to-settle-patent-litigation-with-osmotica","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/","title":{"rendered":"Adamas Announces Agreement to Settle Patent Litigation with Osmotica"},"content":{"rendered":"<h2>\nAs part of this agreement Adamas will acquire the global rights to OSMOLEX ER\u00ae<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">EMERYVILLE, Calif., Dec.  02, 2020  (GLOBE NEWSWIRE) &#8212; Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today\u00a0announced\u00a0it has\u00a0signed an agreement to\u00a0settle its ongoing patent litigation with Osmotica\u00a0Pharmaceutical US LLC, a subsidiary of Osmotica\u00a0Pharmaceuticals plc.\u00a0As a result of this agreement,\u00a0both parties\u00a0will\u00a0drop their respective claims relating to the\u00a0patent\u00a0litigation,\u00a0and Adamas\u00a0will\u00a0acquire the global rights\u00a0to\u00a0OSMOLEX\u00a0ER\u00ae\u00a0for $7.5 million.\u00a0The agreement is expected to close\u00a0early in\u00a02021.\u00a0<\/p>\n<p align=\"justify\">Adamas\u2019 current portfolio consists of GOCOVRI\u00ae (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy. OSMOLEX ER (amantadine) extended-release tablets is FDA-approved for the treatment for Parkinson\u2019s disease and drug-induced extrapyramidal reactions in adult patients.<\/p>\n<p align=\"justify\">\u201cThis settlement agreement removes any further litigation costs and related distraction for Adamas. The acquisition of OSMOLEX ER also expands our presence in Neurology which is part of our long-term growth strategy,\u201d said Neil F. McFarlane, Chief Executive Officer. \u201cThe different FDA-approved indications and pharmacokinetic profiles for GOCOVRI and OSMOLEX ER allow for the treatment of distinct patient populations. We intend to leverage our commercial expertise to unlock the full potential of both products and serve more patients in the wider neurology community.\u201d<\/p>\n<p align=\"justify\">As part of the acquisition, Adamas will receive\u00a0existing inventory and all\u00a0rights\u00a0to\u00a0OSMOLEX ER.\u00a0Parties also entered a supply agreement\u00a0in which\u00a0Osmotica\u00a0will\u00a0be the sole manufacturer of\u00a0OSMOLEX\u00a0ER.\u00a0Both parties are working together to\u00a0ensure\u00a0continuity of\u00a0product\u00a0supply\u00a0to\u00a0patients.\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About GOCOVRI\u00ae\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">GOCOVRI\u00ae (amantadine) extended-release capsules\u00a0is\u00a0the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also the only medicine clinically proven to reduce both dyskinesia and OFF.\u00a0<\/p>\n<p align=\"justify\">Taken once daily at bedtime, GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day. Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The\u00a0most commonly observed\u00a0adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls and orthostatic hypotension.\u00a0<\/p>\n<p align=\"justify\">For more information about GOCOVRI, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yJMyVXtqEsTm1OurjntZv4pwASmWeRyuFsdZDOjKeAsbPP0jrl97BkNsmxKmf8WS01ok9cWXv5JCW6iNbmQImQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.GOCOVRI.com<\/a>.\u00a0\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About OSMOLEX\u00a0ER\u00ae\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">OSMOLEX ER\u00ae,\u00a0(amantadine)\u00a0extended-release\u00a0tablets, is FDA-approved for the treatment of Parkinson\u2019s disease and drug-induced extrapyramidal reactions in adult patients.\u00a0OSMOLEX ER is contraindicated in patients with end-stage renal disease (i.e., creatinine clearance below 15 mL\/min\/1.73 m2). The most common adverse reactions reported in \u22655% of patients at the recommended dosage of immediate-release amantadine were nausea, dizziness\/lightheadedness, and insomnia.\u00a0<\/p>\n<p align=\"justify\">For more information about OSMOLEX ER, including the full Prescribing Information, please visit www.OSMOLEX.com\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About Adamas\u00a0\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">At Adamas our vision is clear &#8211; to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1O4GKRNJq8kSn27Sf9amgjSEqVVwiGNXHDYC3d7ptKGHoAJrkSFivQ1pOpHa0-mQd3iZjBpmgKOnQPVDNGLICBEUBTDD2QLfTEirfsX8vyc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.adamaspharma.com<\/a>.\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking statements\u00a0\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">Statements contained in this press release regarding matters that may occur in the future are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding Adamas\u2019 expectations\u00a0regarding the expected timing of the closing of the transaction with Osmotica. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. For\u00a0example, the completion of the transaction is subject to closing conditions, which if not met or waived, would cause the transaction not to close.\u00a0 Other risks relating to Adamas may be found in\u00a0Adamas\u2019 Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020, particularly under the caption \u201cRisk Factors.\u201d Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Media<\/strong><br \/>\n        <br \/>Sarah Mathieson<br \/>Vice President of Corporate Communications<br \/>510-450-3528<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bPpGlc4REQp2LrYj44u6Iw8GCf4wXts7MVIi0ByZW8nTTfPKUSeDO0kEfaC0dN25DN-3AKTR4mGP7xKMINL4F5m3XnLeeRUlTo1YYVjPo-avyUXmrS6Hi1dKWb5cE-Fi\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">smathieson@adamaspharma.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investors<\/strong><br \/>\n        <br \/>Peter Vozzo<br \/>Managing Director, Westwicke<br \/>443-213-0505<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=luzbLr1sbrfBy9lUoyva08EB-VGVN0SUa-ZoEglMfNjrO46LUl4NhUDBvoy2k0iIv6RryOI2wkwMljHzRELgSByLEOmB5Ib-uhzeCz1zdYA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">peter.vozzo@westwicke.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/44ced619-05af-4258-9b42-a31b00914c0c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>As part of this agreement Adamas will acquire the global rights to OSMOLEX ER\u00ae EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) &#8212; Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today\u00a0announced\u00a0it has\u00a0signed an agreement to\u00a0settle its ongoing patent litigation with Osmotica\u00a0Pharmaceutical US LLC, a subsidiary of Osmotica\u00a0Pharmaceuticals plc.\u00a0As a result of this agreement,\u00a0both parties\u00a0will\u00a0drop their respective claims relating to the\u00a0patent\u00a0litigation,\u00a0and Adamas\u00a0will\u00a0acquire the global rights\u00a0to\u00a0OSMOLEX\u00a0ER\u00ae\u00a0for $7.5 million.\u00a0The agreement is expected to close\u00a0early in\u00a02021.\u00a0 Adamas\u2019 current portfolio consists of GOCOVRI\u00ae (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy. OSMOLEX ER (amantadine) extended-release tablets is FDA-approved for the treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Adamas Announces Agreement to Settle Patent Litigation with Osmotica&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-391468","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adamas Announces Agreement to Settle Patent Litigation with Osmotica - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adamas Announces Agreement to Settle Patent Litigation with Osmotica - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"As part of this agreement Adamas will acquire the global rights to OSMOLEX ER\u00ae EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) &#8212; Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today\u00a0announced\u00a0it has\u00a0signed an agreement to\u00a0settle its ongoing patent litigation with Osmotica\u00a0Pharmaceutical US LLC, a subsidiary of Osmotica\u00a0Pharmaceuticals plc.\u00a0As a result of this agreement,\u00a0both parties\u00a0will\u00a0drop their respective claims relating to the\u00a0patent\u00a0litigation,\u00a0and Adamas\u00a0will\u00a0acquire the global rights\u00a0to\u00a0OSMOLEX\u00a0ER\u00ae\u00a0for $7.5 million.\u00a0The agreement is expected to close\u00a0early in\u00a02021.\u00a0 Adamas\u2019 current portfolio consists of GOCOVRI\u00ae (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy. OSMOLEX ER (amantadine) extended-release tablets is FDA-approved for the treatment &hellip; Continue reading &quot;Adamas Announces Agreement to Settle Patent Litigation with Osmotica&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-02T11:53:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adamas Announces Agreement to Settle Patent Litigation with Osmotica\",\"datePublished\":\"2020-12-02T11:53:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/\"},\"wordCount\":748,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/\",\"name\":\"Adamas Announces Agreement to Settle Patent Litigation with Osmotica - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=\",\"datePublished\":\"2020-12-02T11:53:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adamas Announces Agreement to Settle Patent Litigation with Osmotica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adamas Announces Agreement to Settle Patent Litigation with Osmotica - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/","og_locale":"en_US","og_type":"article","og_title":"Adamas Announces Agreement to Settle Patent Litigation with Osmotica - Market Newsdesk","og_description":"As part of this agreement Adamas will acquire the global rights to OSMOLEX ER\u00ae EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) &#8212; Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today\u00a0announced\u00a0it has\u00a0signed an agreement to\u00a0settle its ongoing patent litigation with Osmotica\u00a0Pharmaceutical US LLC, a subsidiary of Osmotica\u00a0Pharmaceuticals plc.\u00a0As a result of this agreement,\u00a0both parties\u00a0will\u00a0drop their respective claims relating to the\u00a0patent\u00a0litigation,\u00a0and Adamas\u00a0will\u00a0acquire the global rights\u00a0to\u00a0OSMOLEX\u00a0ER\u00ae\u00a0for $7.5 million.\u00a0The agreement is expected to close\u00a0early in\u00a02021.\u00a0 Adamas\u2019 current portfolio consists of GOCOVRI\u00ae (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy. OSMOLEX ER (amantadine) extended-release tablets is FDA-approved for the treatment &hellip; Continue reading \"Adamas Announces Agreement to Settle Patent Litigation with Osmotica\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-02T11:53:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adamas Announces Agreement to Settle Patent Litigation with Osmotica","datePublished":"2020-12-02T11:53:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/"},"wordCount":748,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/","name":"Adamas Announces Agreement to Settle Patent Litigation with Osmotica - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=","datePublished":"2020-12-02T11:53:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTIyMCMzODUyMTE3IzIwMDY5NjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-agreement-to-settle-patent-litigation-with-osmotica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adamas Announces Agreement to Settle Patent Litigation with Osmotica"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=391468"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391468\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=391468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=391468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=391468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}